Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix

This article was originally published in The Pink Sheet Daily

Executive Summary

The preliminary evaluation now goes to Germany’s Federal Joint Committee to make a final decision on the products’ usefulness in the country’s health care system, and their future pricing.

You may also be interested in...



Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck

Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.

Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic

Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.

UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel